WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
WT1 antibody
WT1 peptide cancer vaccine
immune monitoring
immunotherapy
sarcoma
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
09
10
2021
accepted:
03
12
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
ppublish
Résumé
The Wilms' tumor gene WT1 is highly expressed in various malignancies and may be a common target antigen for cancer immunotherapy. In our group, peptide-based cancer vaccines targeting WT1 CTL epitopes were developed as an immunotherapy for these malignancies. In the present study, WT1 epitope-specific immune responses were analyzed in 31 patients with advanced sarcoma with human leukocyte antigen-A*24:02- and WT1-expressing tumors who received the WT1-235 peptide vaccine as monotherapy. The serum levels of IgG and IgM antibodies against the target epitope WT1-235 and the non-target epitopes WT1-332 and WT1-271 were measured using ELISA. IgM antibodies against WT1-235, WT1-332 and WT1-271 were detected in three (9.6%), four (12.9%) and 20 patients (64.5%), respectively, prior to vaccine administration, indicating immune recognition of the WT1 antigen prior to administering the vaccine. Of 15 patients who had completed the 3-month treatment protocol, WT1-235 IgG was positive in five (33.3%) patients. An enzyme-linked immunospot assay revealed that WT1-235 epitope-specific IL-10 production/secretion in peripheral blood mononuclear cells declined in the first month of vaccine administration in all three patients with positivity for WT1-235 IgM at the start of the vaccine. Furthermore, positivity for both WT1-235 and WT1-271 IgM antibodies at the start of treatment was associated with unfavorable tumor control at 3 months after vaccine administration. These results suggested that WT1 epitope-specific IgG and IgM antibodies may be utilized as immune-monitoring markers for WT1 peptide cancer vaccine immunotherapy. The trials were entered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (https://www.umin.ac.jp/ctr; no. UMIN000002001 on May 24, 2009 and no. UMIN000015997 on December 20, 2014).
Identifiants
pubmed: 35069874
doi: 10.3892/ol.2022.13184
pii: OL-23-02-13184
pmc: PMC8756391
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65Informations de copyright
Copyright: © Alzaaqi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Clin Cancer Res. 2009 Sep 1;15(17):5323-37
pubmed: 19723653
Blood. 2011 Aug 11;118(6):1495-503
pubmed: 21673345
Hum Pathol. 2011 Dec;42(12):1960-4
pubmed: 21676435
Nat Rev Cancer. 2019 Dec;19(12):698-715
pubmed: 31666715
Int J Hematol. 2002 Aug;76(2):127-32
pubmed: 12215010
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Cancer Sci. 2003 Aug;94(8):712-7
pubmed: 12901797
J Immunol. 1995 Sep 15;155(6):3112-23
pubmed: 7673726
Int J Cancer. 2016 Sep 15;139(6):1391-401
pubmed: 27170523
Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90
pubmed: 15365188
Eur J Cancer. 2021 Jul;152:165-182
pubmed: 34107450
Leukemia. 2012 Mar;26(3):530-2
pubmed: 21869838
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2699-706
pubmed: 22988094
J Clin Invest. 2018 May 1;128(5):1820-1836
pubmed: 29461978
Int J Cancer. 2009 Jul 15;125(2):381-7
pubmed: 19384943
Cancer Immunol Res. 2018 Mar;6(3):320-331
pubmed: 29358173
Blood. 2017 Oct 12;130(15):1713-1721
pubmed: 28830889
Blood. 2009 Jun 25;113(26):6541-8
pubmed: 19389880
Anticancer Res. 2010 Jun;30(6):2247-54
pubmed: 20651376
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Mod Pathol. 2006 Jun;19(6):804-14
pubmed: 16547468
Blood. 1998 Apr 15;91(8):2969-76
pubmed: 9531608
Nat Rev Clin Oncol. 2021 Apr;18(4):215-229
pubmed: 33473220
Blood Cancer J. 2013 Aug 02;3:e130
pubmed: 23912610
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
J Immunol. 1998 Sep 1;161(5):2099-105
pubmed: 9725200
J Pediatr Surg. 2011 Dec;46(12):2233-8
pubmed: 22152856
J Immunother Cancer. 2016 Jul 19;4:40
pubmed: 27437104
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cell Mol Immunol. 2017 Aug;14(8):662-674
pubmed: 28626234
Cancer. 1991 Aug 1;68(3):463-73
pubmed: 2065265
Front Immunol. 2019 Mar 22;10:529
pubmed: 30967868
Eur J Immunol. 2015 Apr;45(4):999-1009
pubmed: 25545618
Am Soc Clin Oncol Educ Book. 2014;:e488-95
pubmed: 24857144
J Immunother. 2007 Apr;30(3):282-93
pubmed: 17414319
J Cancer Res Clin Oncol. 2013 Mar;139(3):457-63
pubmed: 23160854
BMC Cancer. 2018 Sep 24;18(1):913
pubmed: 30249211
Int Immunol. 2014 Dec;26(12):659-72
pubmed: 24994818
J Immunol. 2015 Apr 1;194(7):3096-101
pubmed: 25732732
Cancer Immunol Immunother. 2019 Feb;68(2):331-340
pubmed: 30430205
Nat Med. 2019 Jul;25(7):1064-1072
pubmed: 31235963
J Neurosurg. 2008 May;108(5):963-71
pubmed: 18447714
Cancer Sci. 2003 Mar;94(3):271-6
pubmed: 12824921
Biomed Rep. 2020 May;12(5):244-250
pubmed: 32257187
J Bone Oncol. 2019 Jan 29;15:100221
pubmed: 30775238
Cancer Immunol Immunother. 2012 Nov;61(11):2079-90
pubmed: 22562379
Int J Hematol. 2001 Feb;73(2):177-87
pubmed: 11372729
Cancer Res. 2011 May 15;71(10):3505-15
pubmed: 21444674
Cancer. 2006 May 15;106(10):2233-40
pubmed: 16607650
Curr Med Chem. 2006;13(20):2345-52
pubmed: 16918359
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Eur J Haematol. 2010 Oct;85(4):358-60
pubmed: 20633041
J Exp Med. 2009 Nov 23;206(12):2779-93
pubmed: 19858324
J Immunother Cancer. 2019 Oct 24;7(1):276
pubmed: 31651363
J Immunol. 2006 Aug 15;177(4):2565-74
pubmed: 16888018
Int J Cancer. 2018 Jun 1;142(11):2375-2382
pubmed: 29322496
Blood Adv. 2018 Feb 13;2(3):224-234
pubmed: 29386195
Cells. 2019 May 13;8(5):
pubmed: 31086070
Anticancer Res. 2018 Apr;38(4):2217-2225
pubmed: 29599342
Cancer Discov. 2016 Mar;6(3):247-55
pubmed: 26715643
Clin Cancer Res. 2016 Mar 15;22(6):1364-70
pubmed: 26534966